SG165328A1 - Treatment of inflammatory bowel disease - Google Patents

Treatment of inflammatory bowel disease

Info

Publication number
SG165328A1
SG165328A1 SG201006316-2A SG2010063162A SG165328A1 SG 165328 A1 SG165328 A1 SG 165328A1 SG 2010063162 A SG2010063162 A SG 2010063162A SG 165328 A1 SG165328 A1 SG 165328A1
Authority
SG
Singapore
Prior art keywords
cells
expanded
patient
inflammatory bowel
activated
Prior art date
Application number
SG201006316-2A
Other languages
English (en)
Inventor
Ola Winqvist
Magnus Thoern
Original Assignee
Ith Immune Therapy Holdings Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ith Immune Therapy Holdings Ab filed Critical Ith Immune Therapy Holdings Ab
Publication of SG165328A1 publication Critical patent/SG165328A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG201006316-2A 2005-08-31 2006-08-22 Treatment of inflammatory bowel disease SG165328A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501916 2005-08-31

Publications (1)

Publication Number Publication Date
SG165328A1 true SG165328A1 (en) 2010-10-28

Family

ID=37809140

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201006316-2A SG165328A1 (en) 2005-08-31 2006-08-22 Treatment of inflammatory bowel disease

Country Status (13)

Country Link
US (1) US8852581B2 (fr)
EP (1) EP1933854B1 (fr)
JP (1) JP5492414B2 (fr)
KR (1) KR101475800B1 (fr)
CN (1) CN101252941A (fr)
AU (1) AU2006285446B2 (fr)
CA (1) CA2619735C (fr)
EA (1) EA015989B1 (fr)
IL (1) IL189611A (fr)
NO (1) NO341189B1 (fr)
SG (1) SG165328A1 (fr)
WO (1) WO2007027132A1 (fr)
ZA (1) ZA200801678B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006285446B2 (en) 2005-08-31 2013-08-22 Tla Targeted Immunotherapies Ab Treatment of inflammatory bowel disease
EP2062970A1 (fr) 2007-11-26 2009-05-27 Txcell Compositions pour traiter une condition inflammatoire intestinale
CN102732480A (zh) * 2012-06-11 2012-10-17 中山大学 N-乙酰半胱氨酸对中央记忆性t细胞的绝对数量在体外扩增上的应用
WO2014104305A1 (fr) * 2012-12-28 2014-07-03 持田製薬株式会社 Diagnostic de la maladie inflammatoire chronique de l'intestin par la mesure de la présepsine
EP3071686B1 (fr) 2013-11-22 2020-07-22 Cellectis SA Procédé de production de lots de lymphocytes t allogéniques de puissance moyennee
CN103911341B (zh) * 2014-01-26 2016-04-13 山东迪博生物科技股份有限公司 Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用
JP2018188408A (ja) * 2017-05-11 2018-11-29 国立大学法人群馬大学 制御性ｔ細胞増強剤並びにそれを含む医薬及び食品組成物
GB201714777D0 (en) * 2017-09-14 2017-11-01 Univ London Queen Mary Agent
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека
CN110051698A (zh) * 2019-03-18 2019-07-26 天津大学 基于微囊化处理的肠道原生菌基因改造的方法
CN111374989B (zh) * 2020-03-16 2022-04-19 中山大学附属第五医院 用于治疗炎症性肠病的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
CA2488823A1 (fr) 2002-06-25 2003-12-31 Index Pharmaceuticals Ab Procede et kit pour diagnostic de colite ulcereuse
ES2282355T3 (es) * 2002-10-11 2007-10-16 Sentoclone Ab Inmunoterapia de cancer.
WO2004050706A2 (fr) 2002-12-03 2004-06-17 Medical Research Council Lymphocytes t regulateurs
WO2005009339A2 (fr) 2003-05-30 2005-02-03 Pathway Diagnostics Corporation, Inc. (a Delaware Corporation) Maladies intestinales inflammatoires
CN1953767B (zh) * 2004-01-08 2011-03-16 加利福尼亚大学董事会 调节t细胞抑制自身免疫
SI1739166T1 (sl) * 2005-07-01 2011-11-30 Txcell S A PRIDOBIVANJE CELIC Tr1 SPECIFIČNIH ZA ALIMENTARNI ANTIGEN ALI AVTOGEN IZ LEVKOCITNE ALI PBMC POPULACIJE
AU2006285446B2 (en) 2005-08-31 2013-08-22 Tla Targeted Immunotherapies Ab Treatment of inflammatory bowel disease
ES2603203T3 (es) 2006-05-12 2017-02-24 Ith Immune Therapy Holdings Ab Método y medio para tratar la enfermedad inflamatoria intestinal
WO2009017444A2 (fr) 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnostic, stadification et surveillance de l'affection abdominale inflammatoire

Also Published As

Publication number Publication date
AU2006285446B2 (en) 2013-08-22
JP2009506109A (ja) 2009-02-12
US8852581B2 (en) 2014-10-07
EP1933854B1 (fr) 2014-06-25
EA200800662A1 (ru) 2008-08-29
ZA200801678B (en) 2008-12-31
JP5492414B2 (ja) 2014-05-14
CN101252941A (zh) 2008-08-27
CA2619735C (fr) 2014-05-27
IL189611A (en) 2011-10-31
EP1933854A4 (fr) 2012-07-25
EA015989B1 (ru) 2012-01-30
CA2619735A1 (fr) 2007-03-08
WO2007027132A1 (fr) 2007-03-08
KR101475800B1 (ko) 2014-12-23
NO20081539L (no) 2008-05-29
NO341189B1 (no) 2017-09-04
IL189611A0 (en) 2008-06-05
EP1933854A1 (fr) 2008-06-25
KR20080047579A (ko) 2008-05-29
US20090311228A1 (en) 2009-12-17
AU2006285446A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
SG165328A1 (en) Treatment of inflammatory bowel disease
WO2006085984A3 (fr) Biocapteurs de cellules immunes et procedes d'utilisation
WO2006076025A3 (fr) Biocapteurs de cellule immune et procede d'utilisation de ceux-ci
MX2021004775A (es) Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
MX2007006355A (es) Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico.
AR043616A1 (es) Anticuerpos contra receptor humano il-21 y usos de los mismos
DE60239741D1 (de) Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe
TW200744634A (en) Methods of using antibodies against human IL-22
CN106661570A8 (zh) 通过与氨甲蝶呤选择偶联的睡美人转座子制备工程化t细胞
ATE526394T1 (de) Verfahren zur expansion von cd4+ cd25+ t regulatory zellen
SG10201809947UA (en) Use of prg4 as an anti-inflammatory agent
WO2012048093A3 (fr) Préparations de msc renforcées
WO2013088148A3 (fr) Méthode de traitement à l'aide d'un produit à base de lymphocytes t thérapeutiques provenant de donneurs mobilisés
TW200728466A (en) Antibody molecules having specificity for human IL-6
MY146664A (en) Antibodies against human il-22 and uses therefor
WO2007084775A3 (fr) Compositions et procedes permettant de moduler l’activation d'un lymphocyte t suppresseur
IL184273A0 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
TN2009000380A1 (en) Novel human anti-r7v antibodies and uses thereof
WO2006029029A3 (fr) Compositions permettant de detecter une reactivation latente du vih et procedes d'utilisation de celles-ci
Gore et al. Mesenchymal stem cells enhance lung recovery after injury, shock, and chronic stress
MX2022006547A (es) Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
WO2004032599A3 (fr) Nouvelles proteines immunogenes de leptospira
NZ593749A (en) Soluble icam-1 as biomarker for prediction of therapeutic response
WO2022229884A3 (fr) Cellules de présentation d'antigène recombinant
WO2007025705A3 (fr) Procede de production de lymphocytes t specifiques a l'antigene et utilisations